Genomics
What genetic variants and vulnerabilities are present?
Healthcare Providers
Complex Patients Don’t Need Another Protocol.
They need a strategy built from their biology.
Your most difficult cases may share a diagnosis with thousands of other patients—but they do not share the same active signaling, immune presentation, molecular drivers, or treatment history.
Neo7 looks beneath the diagnosis to identify what is driving this patient’s condition—and designs a personalized, multi-target strategy around what matters most.
The Trigger Is Not the Whole Story
A virus, antigen, toxin, infection, genetic variant, or environmental exposure may explain how illness began.
But why does one patient recover while another remains ill? Why do patients with the same diagnosis respond differently to the same treatment?
The trigger may have started the process. The patient's active biology may be what is sustaining it.
Neo7 asks the next question: What is happening within this patient now that may be allowing disease or dysfunction to persist?
We evaluate how genes are behaving, which proteins are being produced, how the immune system recognizes targets, and—when applicable—what cancer-related signals are circulating in the blood.
Multiomic Analysis: Connecting the Biology Behind the Diagnosis
One patient. Multiple biological layers. One clinically relevant picture.
Most testing answers one question at a time: Is a mutation present? Is a biomarker elevated? Is an organism detectable? Is a pathway abnormal?
Multiomic analysis evaluates several layers of the patient's biology together:
Transcriptomics
Which genes and pathways are actively signaling now?
Proteomics
What functional protein activity, tissue stress, damage, or repair is occurring downstream?
HLA profiling
How might the patient's immune system present and recognize potential peptide targets?
Cancer-specific analysis
What tumor-derived DNA, RNA, or tissue signals are present when applicable?
Clinical context
How do these findings relate to the patient's symptoms, diagnosis, known mutations, treatment history, and current therapies?
The value is not simply collecting more data. It is finding where multiple biological layers point to the same dysregulated pathway—and determining which signals are most relevant, connected, and therapeutically actionable.
A single result identifies a finding. Multiomic analysis reveals the biological relationships that may be driving the patient's condition.
More Than Testing. More Than Another Peptide Protocol.
Conventional approach
Neo7 approach
Begins with the diagnosis
Looks for the patient-specific biology behind it
Focuses on the suspected trigger
Investigates what may be sustaining dysfunction now
Reviews isolated markers or pathways
Evaluates multiple biological layers together
Identifies inherited risk
Examines active gene and protein expression
Matches diagnoses to standardized protocols
Selects targets based on the individual patient
Addresses one abnormality at a time
Targets interconnected biological signals
Uses standardized or stacked peptides
Designs a personalized pooled peptide therapy
Treats biology as static
Supports reassessment as biology evolves
We do not stop at asking what started the disease. We investigate what may be keeping it active.
Same Diagnosis. Different Biology.
Two patients may share the same diagnosis but have very different biological drivers.
One may demonstrate greater immune dysfunction. Another may show neurological, vascular, inflammatory, metabolic, oxidative, or protein-level disruption.
A diagnosis tells us what the condition is called. It does not fully explain how it is operating within that individual.
Neo7 identifies patient-specific targets and the cross-cluster relationships connecting them—allowing a limited number of carefully selected targets to influence a much broader network of biological signaling.
A Personalized Therapy—Not a Standard Formula
Neo7 is not an off-the-shelf peptide program and does not simply stack commonly used peptides.
Each therapy is designed from the patient's own biological findings. Selected targets are translated into a personalized, multi-target pooled peptide formulation intended specifically for that individual.
Patient-specific target selection
Multi-target pooled peptide design
HLA-informed immune compatibility
Designed to work alongside existing care
Reanalysis as the patient's biology evolves
Advanced Science With Provider Oversight
Neo7 extends what you can see without replacing your clinical judgment.
Providers Receive
Click a card to see what it means for your practice
A Deeper View of the Patient
Connect genomic, RNA, protein, immune-presentation, disease-specific, and clinical information to see patterns that isolated test results may miss.
Prioritized Biological Targets
Receive a focused group of patient-specific targets ranked for biological relevance, pathway connectivity, HLA compatibility, and therapeutic actionability.
A Personalized Multi-Target Peptide Design
Each design is created from the patient’s molecular findings—not selected from a standard protocol, off-the-shelf formula, or generic peptide stack.
Multidisciplinary Expert Review
Analytical findings are reviewed through augmented intelligence and a team that may include molecular PhDs, mathematicians, statisticians, geneticists, pharmacists, and medical providers.
Clinical Implementation Guidance
Receive support for route, dosing, low-and-slow implementation, administration planning, and coordination with the patient’s existing therapies.
Monitoring and Response Support
Use symptoms, function, routine laboratories, imaging, disease-specific markers, and molecular findings to evaluate response within the patient’s complete clinical picture.
Reassessment and Adaptive Redesign
Biology changes. Repeat testing can identify improved, persistent, or newly active signals and help determine whether the target strategy should be continued, refined, or redesigned.
Ongoing Provider Education
Access onboarding, scientific education, case discussions, report interpretation, implementation support, and continuing provider resources.
You retain the patient relationship and clinical oversight. Neo7 provides the molecular analysis, target prioritization, and personalized design support.
Clinical Inquiries & Onboarding
Let’s Learn About Your Practice
Tell us a little about your practice, your patients, and what brought you to Neo7. We will connect you with the right clinical information and next step.
Start Provider InquiryFrom Patient Evaluation to Personalized Design
Built for the Cases That Do Not Fit Neatly Into a Protocol
Neo7 works with licensed providers supporting patients with:
Neo7 may be especially relevant when the clinical picture remains incomplete, multiple approaches have been attempted, or standardized protocols have not produced the desired progress.
Cancer and active disease
Autoimmune and inflammatory conditions
Chronic and medically complex illness
Post-viral and spike-related complications
Neurological, vascular, and congenital conditions
Resilience, longevity, and optimization goals
Have a Patient Who Keeps You Thinking After Hours?
You do not need to understand the entire Neo7 platform before beginning a conversation.
Bring us a challenging case. We will help you explore whether the patient may be appropriate for Neo7.
Partner With Neo7Bioscience
Neo7 partners with integrative, functional, oncology, and precision-focused providers who want to bring deeper biological insight and personalized therapeutic design into their practices.
A licensed prescriber is required. Neo7 protocols are provided under physician oversight and IRB governance.
Provider Onboarding Includes
Clinical and scientific introduction
NDA, BAA, and IRB documentation
Platform and process training
Patient ordering and prescription workflow
Case consultation and implementation support
Provider education and collaboration opportunities
FAQs
Neo7 does not evaluate one marker or biological layer in isolation. It brings multiple layers together to identify active dysfunction and prioritize patient-specific therapeutic targets. Read the Full Answer
No. Testing, integrated analysis, target prioritization, therapeutic design, and reassessment are parts of one personalized program. Learn About the Complete Program
No. Each pooled peptide therapy is designed from the individual patient's biological findings and selected targets. Learn About Personalized Peptide Design
No. Neo7 selects multiple patient-specific targets based on their relationships across broader biological signaling networks. Explore Multi-Target Design
The licensed provider reviews the patient's clinical history, prescribes the therapy, directs implementation, and maintains clinical oversight. View the Provider Workflow
Yes. Providers may bring a potential case to Neo7 for an introductory discussion before completing the full onboarding process. Discuss a Patient Case
Look Beyond the Diagnosis
See what may be driving the individual patient's biology.
And what could be addressed differently.
Reach out to discuss a case or explore how Neo7 could fit into your practice.
Let’s Learn About Your Practice
Tell us a little about your practice, your patients, and what brought you to Neo7. We will use your answers to connect you with the right information and next step.